Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal
Just days ahead of Vas Narasimhan’s jump into the CEO’s spot, Novartis has swooped in with a $170 million deal to grab ex-US rights on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
